{
    "id": "correct_subsidiary_00025_3",
    "rank": 22,
    "data": {
        "url": "https://www.linkedin.com/posts/astorg_avania-acquires-maxis-advancing-medtech-activity-7035935698977181696-YCuU",
        "read_more_link": "",
        "language": "en",
        "title": "Astorg on LinkedIn: Avania Acquires MAXIS, Advancing MedTech Leadership in Pre",
        "top_image": "https://media.licdn.com/dms/image/C4E22AQGrM9oiWohzkw/feedshare-shrink_800/0/1677497534785?e=2147483647&v=beta&t=3VmYBcKQiH6_bbyQFJWgiBLy0b9FzL1wLQiDlI0HRvk",
        "meta_img": "https://media.licdn.com/dms/image/C4E22AQGrM9oiWohzkw/feedshare-shrink_800/0/1677497534785?e=2147483647&v=beta&t=3VmYBcKQiH6_bbyQFJWgiBLy0b9FzL1wLQiDlI0HRvk",
        "images": [
            "https://media.licdn.com/dms/image/C4E1BAQH5lDVu5NCapQ/company-background_10000/0/1631012903940/astorg_cover?e=2147483647&v=beta&t=G_6IGylS1oabuJ6wD0qxY6N-Ncr3Wnx_6JyqlmwSV90"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            ""
        ],
        "tags": null,
        "authors": [
            "Astorg"
        ],
        "publish_date": "2023-02-27T11:36:31.978000+00:00",
        "summary": "",
        "meta_description": "Astorg is excited to announce that Avania, an Astorg portfolio company, has acquiredÂ MAXIS Medical, a leading medical technology development service provider.â€¦",
        "meta_lang": "en",
        "meta_favicon": "https://static.licdn.com/aero-v1/sc/h/al2o9zrvru7aqj8e1x2rzsrca",
        "meta_site_name": "",
        "canonical_link": "https://www.linkedin.com/posts/astorg_avania-acquires-maxis-advancing-medtech-activity-7035935698977181696-YCuU",
        "text": "ğ—”ğ˜€ğ˜ğ—¼ğ—¿ğ—´ ğŸ®ğŸ¬ğŸ®ğŸ° ğ—”ğ—»ğ—»ğ˜‚ğ—®ğ—¹ ğ—–ğ—™ğ—¢ ğ—™ğ—¼ğ—¿ğ˜‚ğ—º Astorg recently held its third Annual CFO Forum in London. We had the pleasure of welcoming representatives from more than 20 of our portfolio companies for a moment of insights and sharing. The forum was packed with dynamic sessions and thought-provoking panels led by renowned experts. We delved deep into a variety of topics, including: ğŸ” Economic Outlook: analyzing current trends and future projections to navigate the evolving financial landscape. ğŸ¦¾ AI Strategies for CFOs: exploring cutting-edge AI technologies and their applications in financial management. ğŸ’¡ Cash Management: best practices for optimizing liquidity and ensuring financial stability. ğŸ“ˆ Value Growth Planning: innovative approaches to drive sustainable growth and enhance company value. ğŸŒ CSRD Implications for ESG Reporting: understanding the latest regulations and integrating ESG considerations into financial reporting. At Astorg, we believe in the power of collaboration and our CFO Forum exemplifies our commitment to fostering a strong, connected community of financial leaders who are equipped to drive innovation and success in their respective fields. Together with our CFO community we exchanged insights, fresh perspectives, shared best practices, and actionable strategies. A big thank you to all our speakers, panelists, and attendees! Thibault Veber, Alexandre F., Parinaz Bhot, Edouard Pillot, Benjamin Cordonnier, Viviana Occhionorelli, Valerie Legat #AstorgCFOForum #StrategicFinance #PortfolioGrowth #FinanceLeadership #Innovation\n\nğŸ“£ ğ—”ğ˜€ğ˜ğ—¼ğ—¿ğ—´ ğ—£ğ—¼ğ—¿ğ˜ğ—³ğ—¼ğ—¹ğ—¶ğ—¼ ğ—–ğ—¼ğ—ºğ—½ğ—®ğ—»ğ˜† ğ—¡ğ—²ğ˜„ğ˜€ Astorg is pleased to share that its portfolio company Corden Pharma - A Full-Service CDMO has announced its largest strategic investment to date - with a committed spend of ~â‚¬900m over the next three years to grow its Peptide technology platform both at its Colorado site and in Europe. CordenPharma is a CDMO partner supporting biotech and pharma innovators of complex modalities in advancing their drug development lifecycle. Supported by Astorg since its acquisition in 2022, CordenPharma has strongly accelerated its transformation and is committed to pursuing its ambitious growth plans aiming to reach ~â‚¬1bn sales mark for its pioneering Peptide Platform, and ~â‚¬1.8bn total group revenue by 2028. This expansion will meet the pharmaceutical industryâ€™s most stringent quality and technical standards for short and long peptide manufacturing, including BLA requirements, and will help to strengthen CordenPharma's market leadership position. ğŸ™ Judith Charpentier, Co-Head of Astorg's Flagship Fund & Head of Healthcare: â€œCordenPharma has a unique opportunity to reinforce its leadership position in peptides with unmatched capacity and performance in large scale manufacturing. With the companyâ€™s proven track record and our investor experience in pharmaceutical services, we feel confident that our latest commitment will help the company seize this opportunity.â€ Congratulations to Michael Quirmbach and the entire CordenParmaâ€™s team! ğŸ‘‡ Read more about CordenPharmaâ€™s transformational peptide platform expansion by clicking the link below. #PrivateEquity #Growth #Healthcare #CDMO #Peptides #Pharmaceutical #Innovation Dr. Signe Michel Antoine Thomas Olivier Gourgue Michael Quirmbach Brian McCudden\n\nğŸ“£ ğ—”ğ˜€ğ˜ğ—¼ğ—¿ğ—´ ğ—£ğ—¼ğ—¿ğ˜ğ—³ğ—¼ğ—¹ğ—¶ğ—¼ ğ—–ğ—¼ğ—ºğ—½ğ—®ğ—»ğ˜† ğ—¡ğ—²ğ˜„ğ˜€ Astorg is pleased to announce the ğ˜€ğ˜‚ğ—°ğ—°ğ—²ğ˜€ğ˜€ğ—³ğ˜‚ğ—¹ ğ—°ğ—¹ğ—¼ğ˜€ğ—¶ğ—»ğ—´ ğ—¼ğ—³ ğ˜ğ—µğ—² Normec ğ—–ğ—¼ğ—»ğ˜ğ—¶ğ—»ğ˜‚ğ—®ğ˜ğ—¶ğ—¼ğ—» ğ—™ğ˜‚ğ—»ğ—± ğ—®ğ˜ â‚¬ğŸ­.ğŸ°ğ—¯ğ—» in partnership with CVC Capital Partners, Pantheon, Lexington Partners and Eurazeo alongside a diverse group of additional investors, including sovereign wealth funds, pension funds, asset managers, and family offices. Normec is a leading, pan-European independent Testing, Inspection, Certification, and Compliance (TICC) player that employs over 5,000 people across 6 European countries. Since Astorgâ€™s initial investment in 2020, Normec has performed strongly, more than quadrupling its size, thanks to solid organic growth and a successful acquisitive strategy (40+ acquisitions), with international expansion across 4 verticals. The Continuation Fund raised includes substantial additional capital to further support Normecâ€™s organic growth initiatives and acquisitions. ğŸ™ï¸ Francois de Mitry, CIO of Astorg: â€œFollowing the â‚¬1.3bn continuation fund raised to support IQ-EQ in 2022, establishing our second continuation fund for Normec marks a significant milestone for Astorg, and we are grateful to our existing and new partners for their support. We are thrilled to continue our partnership with Normec as it embarks on its next phase of growth, and we thank Joep Bruins â€“ CEO of Normec - and his team for their dedication and renewed trust.â€ ğŸ‘‡Read the full ğ—£ğ—¿ğ—²ğ˜€ğ˜€ ğ—¥ğ—²ğ—¹ğ—²ğ—®ğ˜€ğ—² by clicking the link below. #PrivateEquity #Deal #ContinuationFunds #TICC #InternationalGrowth Benjamin Cordonnier Mariann Ternai Joep Bruins Britt Schuurs Robert Wolff Frederik Bernoski Jean Raby Thierry Timsit Samia Hadj Niels Langereis Lazard Jefferies\n\nğŸ“£ ğ—”ğ˜€ğ˜ğ—¼ğ—¿ğ—´ ğ—£ğ—¼ğ—¿ğ˜ğ—³ğ—¼ğ—¹ğ—¶ğ—¼ ğ—–ğ—¼ğ—ºğ—½ğ—®ğ—»ğ˜† ğ—¡ğ—²ğ˜„ğ˜€ Astorg is pleased to share that it has signed an agreement to acquire a further stake in Acturis and will now own approximately 52% of the capital of the company. Alongside Acturis management and colleagues, the co-founders, Theo Duchen and David McDonald, will remain significant shareholders with a sizable minority stake, and continue to partner closely with Astorg to support existing clients and drive the company's international growth. Acturis is a leading supplier of insurance software and has seen strong growth since Astorg first invested in the company in 2019, expanding into Germany, France, Canada, Ireland, and the United States and accelerating development of industry leading products and services to meet the growing demand for electronic trading of insurance policies. Astorgâ€™s increased investment represents a doubling down on the long-term opportunities we see in Acturis, notably through organic growth as well as a global acquisition strategy. ğŸ™ï¸Benoit Ficheur says: â€œActuris is a very unique software company with the exact qualities that we look for in a partner, including a high-quality team and strong fundamentals. This reinforced partnership will enable us to support Acturis in its accelerated growth. We have been lucky to work with Acturis over the last 5 years and we look forward to continuing working alongside Theo, David, and the wider team to support existing customers and further expand by entering new markets and segments of the industry.â€ ğŸ‘‡Read the full ğ—£ğ—¿ğ—²ğ˜€ğ˜€ ğ—¥ğ—²ğ—¹ğ—²ğ—®ğ˜€ğ—² by clicking the link below. #PrivateEquity #Deal #Software #Insurance #InternationalGrowth Henry Davies Max Loick Jean Raby Francois de Mitry Thierry Timsit Theo Duchen David McDonald Tony Goddard Hayden Parra Jeff McCracken Mark Davies Shay Bhatia Caroline South Andrew Passfield Olivier Gourgue\n\nğŸŒ ğ—”ğ˜€ğ˜ğ—¼ğ—¿ğ—´'ğ˜€ ğŸ®ğŸ¬ğŸ®ğŸ° ğ—¦ğ˜‚ğ˜€ğ˜ğ—®ğ—¶ğ—»ğ—®ğ—¯ğ—¶ğ—¹ğ—¶ğ˜ğ˜† ğ—¥ğ—²ğ—½ğ—¼ğ—¿ğ˜ ğ—¶ğ˜€ ğ—®ğ˜ƒğ—®ğ—¶ğ—¹ğ—®ğ—¯ğ—¹ğ—² At Astorg, sustainability principles are embedded in everything we do, all the way from our investment process to our engagement with our portfolio companies, to our own company culture. ğŸ™ Viviana Occhionorelli, Partner, Head of Sustainability says: â€œBuilt on years of dialogue with our LPs, portfolio companies, peers and business partners, Astorgâ€™s sustainability strategy is focused on strengthening long-term performance and value creation across our portfolioâ€. Our latest report showcases the significant steps we've made toward building a more sustainable future. Some of the key 2024 highlights include: ğ—œğ—»ğ˜ğ—²ğ—´ğ—¿ğ—®ğ˜ğ—²ğ—± ğ—©ğ—®ğ—¹ğ˜‚ğ—² ğ—–ğ—¿ğ—²ğ—®ğ˜ğ—¶ğ—¼ğ—» Sustainability now sits squarely within our newly created Portfolio Performance function - headed by Benjamin Cordonnier - underscoring its role in driving value. ğ—–ğ—¹ğ—¶ğ—ºğ—®ğ˜ğ—² ğ—”ğ—°ğ˜ğ—¶ğ—¼ğ—» 44% of our portfolio companies' GHG emissions are now covered by SBTi targets. ğ——ğ—¶ğ˜ƒğ—²ğ—¿ğ˜€ğ—¶ğ˜ğ˜† & ğ—œğ—»ğ—°ğ—¹ğ˜‚ğ˜€ğ—¶ğ—¼ğ—» 28% of board members appointed by Astorg are women, reinforcing our commitment to Diversity, Equity and Inclusion. ğ—–ğ—¹ğ—¶ğ—²ğ—»ğ˜ ğ—–ğ—²ğ—»ğ˜ğ—¿ğ—¶ğ—°ğ—¶ğ˜ğ˜† Keeping close to our investors and ensuring all stakeholdersâ€™ interests are aligned is key. We launched a dedicated investor event focused on sustainability alongside our annual portfolio gathering. ğ—”ğ˜€ğ˜ğ—¼ğ—¿ğ—´ ğ—™ğ—¼ğ˜‚ğ—»ğ—±ğ—®ğ˜ğ—¶ğ—¼ğ—» Over â‚¬800,000 allocated via our Foundation to 14 organizations across 6 countries, making a tangible difference in communities. Thank you to our portfolio companies Normec, Solina, Corialis Group and Corsearch for their precious contribution to our report. Thierry Timsit, Jean Raby, Sonia D'Emilio, Judith Charpentier, Lorenzo Zamboni, Marc Rocaniere, Valerie Legat, Alexandre F., Parinaz Bhot, Nathalie Medawar, Cristina Spiller, Michel Sudol, Philip Sheppard #PrivateEquity #ResponsibleInvesting #Sustainability #ESG #DEI #Climate ğŸ‘‡Read our 2024 Sustainability Report here.\n\nğŸ“° ğ—£ğ—¿ğ—²ğ˜€ğ˜€ ğ—¥ğ—²ğ—¹ğ—²ğ—®ğ˜€ğ—² Astorg ğ—¶ğ˜€ ğ—½ğ—¹ğ—²ğ—®ğ˜€ğ—²ğ—± ğ˜ğ—¼ ğ˜„ğ—²ğ—¹ğ—°ğ—¼ğ—ºğ—² ğ˜ğ˜„ğ—¼ ğ—»ğ—²ğ˜„ ğ˜€ğ—²ğ—»ğ—¶ğ—¼ğ—¿ ğ—µğ—¶ğ—¿ğ—²ğ˜€ ğ˜ğ—¼ ğ˜ğ—µğ—² ğ—³ğ—¶ğ—¿ğ—º: Chris Benson, Partner for the Mid-Cap Fund, leading the Business Services sector across Europe, and Daniel Pang, Managing Director in the Healthcare team for the Flagship Fund. ğŸ™ï¸ Lionel de Posson and Edouard Pillot, Co-Heads of Astorg Mid-Cap: â€œWe are delighted to welcome Chris to the team. His deep industry knowledge and network, as well as his investment track-record, will be very additive to our team as we continue to strengthen our focus on business services across Europe. Astorg has already built a strong track-record in the sector, and we see great investment opportunities ahead in the middle market. Chrisâ€™ personality and experience fit very well with Astorgâ€™s entrepreneurial and thematic approach to investing, and we look forward to working with him.â€ ğŸ™ï¸Judith Charpentier, Head of Healthcare and Co-Head of Flagship Fund: â€œDaniel has a wealth of experience identifying and building value across many sub-sectors of the healthcare industry and we are pleased to have him on board. His expertise will be a great asset as we continue to capitalise on the vast opportunities within the healthcare sector and deliver on our mission to build global B2B niche leaders in the space.â€ They both bring deep industry knowledge across their areas of specialization and reflect our commitment to reinforcing our investment expertise and expanding our strategic reach in key sectors. ğŸ‘‡ğ—§ğ—¼ ğ—¿ğ—²ğ—®ğ—± ğ˜ğ—µğ—² ğ—³ğ˜‚ğ—¹ğ—¹ ğ—½ğ—¿ğ—²ğ˜€ğ˜€ ğ—¿ğ—²ğ—¹ğ—²ğ—®ğ˜€ğ—²: click on the link below.\n\nğŸ¥ ğŸ¬ ğ—”ğ˜€ğ˜ğ—¼ğ—¿ğ—´ ğŸ®ğŸ¬ğŸ®ğŸ° ğ—”ğ—»ğ—»ğ˜‚ğ—®ğ—¹ ğ—šğ—²ğ—»ğ—²ğ—¿ğ—®ğ—¹ ğ— ğ—²ğ—²ğ˜ğ—¶ğ—»ğ—´ Astorg recently held its ğ—”ğ—»ğ—»ğ˜‚ğ—®ğ—¹ ğ—šğ—²ğ—»ğ—²ğ—¿ğ—®ğ—¹ ğ— ğ—²ğ—²ğ˜ğ—¶ğ—»ğ—´ at Fondation Louis Vuitton, in Paris, welcoming over 200 participants, including Astorgâ€™s top investors across Europe, the US, and Asia. ğŸ“Œ ğ—¢ğ—» ğ˜ğ—µğ—² ğ—”ğ—´ğ—²ğ—»ğ—±ğ—®: â–ªï¸Break-out sessions with Astorg portfolio company CEOs â–ªï¸Key insights into the Astorg portfolio â–ªï¸Fund performance and outlook â–ªï¸How to adapt to the Private Equity ever-changing landscape â–ªï¸Growth and innovation stories about Astorgâ€™s investments in its key sectors â–ªï¸Deep dive into value creation plans and digital and ESG transformation These are some of the themes discussed during our Annual Meeting moderated by our Master of Ceremony Asha Sumputh ğŸ† To wrap-up our 2024 AGM, we were honored to host ğ—¶ğ—»ğ˜ğ—²ğ—¿ğ—»ğ—®ğ˜ğ—¶ğ—¼ğ—»ğ—®ğ—¹ ğ˜€ğ—½ğ—¼ğ—¿ğ˜ ğ—¹ğ—²ğ—´ğ—²ğ—»ğ—±ğ˜€ â€“ ğ—§ğ—µğ—¶ğ—²ğ—¿ğ—¿ğ˜† ğ—›ğ—²ğ—»ğ—¿ğ˜† ğ—®ğ—»ğ—± Tony Parker â€“ ğ—®ğ˜€ ğ—¼ğ˜‚ğ—¿ ğ—¦ğ—½ğ—²ğ—°ğ—¶ğ—®ğ—¹ ğ—šğ˜‚ğ—²ğ˜€ğ˜ğ˜€. Their insights on achieving peak performance and breaking records in football and basketball were inspiring and resonated deeply with Astorgâ€™s main characteristics such as focus, discipline, excellence, resilience. ğŸ¤ ğ—§ğ—µğ—®ğ—»ğ—¸ ğ˜†ğ—¼ğ˜‚ ğ˜ğ—¼ ğ—®ğ—¹ğ—¹ ğ—½ğ—®ğ—¿ğ˜ğ—¶ğ—°ğ—¶ğ—½ğ—®ğ—»ğ˜ğ˜€ ğ—®ğ—»ğ—± ğ—³ğ—¼ğ—¿ ğ—¯ğ—²ğ—¶ğ—»ğ—´ ğ—®ğ—» ğ—¶ğ—»ğ˜ğ—²ğ—´ğ—¿ğ—®ğ—¹ ğ—½ğ—®ğ—¿ğ˜ ğ—¼ğ—³ ğ˜ğ—µğ—² ğ—”ğ˜€ğ˜ğ—¼ğ—¿ğ—´ ğ—·ğ—¼ğ˜‚ğ—¿ğ—»ğ—²ğ˜†. ğŸ¬ Watch the ğ—¯ğ—²ğ˜€ğ˜-ğ—¼ğ—³ ğ˜ƒğ—¶ğ—±ğ—²ğ—¼ to relive this great event! ***** Thierry Timsit Francois de Mitry Jean Raby Judith Charpentier Lorenzo Zamboni Lionel de Posson Edouard Pillot Benoit Ficheur Benjamin Cordonnier Viviana Occhionorelli Valerie Legat Ludovic Blanquet Sebastiaan V. Samia Hadj Mark Preskop from IQ-EQ, Marc HÃ¤mel from NEMERA, Michael Quirmbach from Corden Pharma - A Full-Service CDMO, Christopher Fikry, M.D. from Clario With the support of our event partners: FinEvents Minds LB Groupe - ğŸŒŸ Conseil Ã©ditorial - Production - Diffusion/WebTV ğŸ¥\n\nğŸ“° ğ—œğ—» ğ˜ğ—µğ—² ğ— ğ—²ğ—±ğ—¶ğ—® Astorg is pleased to ğ—ºğ—®ğ—¸ğ—² ğ—¶ğ˜ğ˜€ ğ—²ğ—»ğ˜ğ—¿ğ˜† ğ—¶ğ—»ğ˜ğ—¼ ğ˜ğ—µğ—² ğ—§ğ—¼ğ—½ ğŸ±ğŸ¬ ğ—£ğ—¿ğ—¶ğ˜ƒğ—®ğ˜ğ—² ğ—˜ğ—¾ğ˜‚ğ—¶ğ˜ğ˜† ğ—³ğ—¶ğ—¿ğ—ºğ˜€ in the ğŸ®ğŸ¬ğŸ®ğŸ° ğ—²ğ—±ğ—¶ğ˜ğ—¶ğ—¼ğ—» ğ—¼ğ—³ Private Equity Internationalâ€™s ğ—¿ğ—®ğ—»ğ—¸ğ—¶ğ—»ğ—´ ğ—¼ğ—³ ğ˜ğ—µğ—² ğ˜„ğ—¼ğ—¿ğ—¹ğ—±â€™ğ˜€ ğ—¹ğ—®ğ—¿ğ—´ğ—²ğ˜€ğ˜ ğ—£ğ—¿ğ—¶ğ˜ƒğ—®ğ˜ğ—² ğ—˜ğ—¾ğ˜‚ğ—¶ğ˜ğ˜† ğ—³ğ—¶ğ—¿ğ—ºğ˜€. Each year, the PEI 300 ranking provides an overview of GPs' fundraising activities through a wide lens, examining capital-raising totals over the past five years' highs and lows. The top 10 alone raised $741 billion, up more than $10 billion from the previous ranking. Our ranking has risen by 11 places since the 2023 edition and being recognised as one of the Top 50 Private Equity firms worldwide is a significant milestone in Astorgâ€™s growth journey. Some highlights over the past year include closing our flagship fund, Astorg VIII, with a total committed capital of â‚¬4.4 billion, making it our largest fund to date, but also strengthening our team with new senior hires in strategic areas - such as investment, investor relations, and digital â€“ and appointment of new members to our Executive Committee, paving the way for the next generation of leaders. The Astorg team remains dedicated to delivering on our mission: generating long-term performance, driving value creation, and fostering innovation as we build the global B2B niche leaders of today and tomorrow. A big thank you to our investors and portfolio partners, who we are proud to work alongside. ğŸ‘‰To read the full PEI report and ranking follow this link: https://lnkd.in/gid7hvp #PEI300 #PrivateEquity #Ranking\n\nğŸ”œ ğ—¦ğ˜‚ğ—½ğ—²ğ—¿ğ—¥ğ—²ğ˜ğ˜‚ğ—¿ğ—» ğ—œğ—»ğ˜ğ—²ğ—¿ğ—»ğ—®ğ˜ğ—¶ğ—¼ğ—»ğ—®ğ—¹, ğ—•ğ—²ğ—¿ğ—¹ğ—¶ğ—», ğ—ğ˜‚ğ—»ğ—² ğŸ° â€“ ğŸ³ The Astorg team is looking forward to engaging with you at SuperReturn International in Berlin next week! This landmark event attracting over 3,000 LPs and leaders in private equity and alternative investing will delve into the top trends shaping our industry, including GenAI, sustainable investing, and the evolution of private equity during challenging times. If youâ€™re attending SuperReturn International, we invite you to visit our booth and/or connect with our team members on the ground â€“ Lionel de Posson Edouard Pillot Judith Charpentier Michal Lange Sebastiaan V. Reinard Volschenk Corinne Schreiber JosÃ©phine LorÃ©al Samia Hadj Alexandre Dussaucy Molly Adams Paul Ansah Tori Steward Join us for meaningful discussions and networking opportunities! #SuperReturn #PrivateEquity #Astorg #Networking #Investment\n\nğŸ“° ğ—œğ—» ğ˜ğ—µğ—² ğ—ºğ—²ğ—±ğ—¶ğ—® Thierry Timsit, CEO of Astorg spoke with Alexandre Garabedian and Florent Le Quintrec from L'AGEFI for an exclusive interview. Thierry shared his views on the private equity industry, the market environment, and gave an insight into Astorgâ€™s business and corporate development. Amid a tough dealmaking market over the past few years, Astorg has proven resilient by doubling down on its commitment to investing in high quality assets and prioritising value creation. ğŸ™ Thierry Timsit says: â€œIn 2024, everything changes. Interest rates have peaked and are stabilizing, reducing volatility, excluding exogenous factors. The value of the assets is now known, and deals are starting again. Transactions will first restart on the most attractive companies. Astorg is well positioned to take advantage of this as we invest in B2B companies with global reach and leadership positions in niche markets, across our four key sectors: healthcare, technology, business services and industrials.â€ ğŸ‘‡ To read the full interview published in Lâ€™Agefi Private Equity, please click below. Scroll to page 7 to read the English translation."
    }
}